Clinical Trials in France — Country Dashboard | 4,500 EU Studies

Filter these 4,500 trials by condition, phase, sponsor and more.

Open in Search →

4,500 Registered trials

1,851 Recruiting

2,152 Completed trials

906 Sponsors active

1,196 Research sites

Phase III

Phase II

Phase III: 1870 Phase II/III: 208 Phase II: 1265 Phase I/II: 286 Phase III/IV: 51 Phase IV: 173 Phase I: 239 Phase I (Other): 177 Phase I (FiH): 218 Other: 8 Other: 5

Oversight events in trials active here:

104 serious breaches 884 temporary halts 92 urgent safety measures 105 unexpected events 179 corrective measures across 542 trials

View oversight register →

Top conditions

Non-small cell lung cancer 154 Non-small cell lung cancer metastatic 52 Colorectal cancer 39 Ovarian cancer 37 Squamous cell carcinoma of head and neck 32 Systemic lupus erythematosus 30 Endometrial cancer 28 Breast cancer 28 Non-small cell lung cancer stage IV 27 Myelodysplastic syndrome 27 Diffuse large B-cell lymphoma 26 Triple negative breast cancer 26

Top sponsors

Assistance Publique Hopitaux De Paris 264 Centre Hospitalier Universitaire De Nantes 195 Merck Sharp & Dohme LLC 178 Novartis Pharma AG 165 F. Hoffmann-La Roche AG 144 AstraZeneca AB 142 Janssen - Cilag International 115 AbbVie Deutschland GmbH & Co. KG 97 Sanofi-Aventis Recherche & Developpement 72 Glaxosmithkline Research & Development Limited 66 Bristol-Myers Squibb Services Unlimited Company 65 Unicancer 65

Cities with most trials

All 448 cities →

All trials — page 60

4,500 total

A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting

2024-511534-12-00 Phase I (FiH) Advanced or Metastatic Solid Tumours Artios Pharma Limited
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Phase III Unresectable, Locally Advanced or Metastatic HER2 positive G… Daiichi Sankyo Inc.
A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia Recruiting

2024-518929-15-00 Phase II Narcolepsy and Idiopathic Hypersomnia Centessa Pharmaceuticals UK Limited
REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting

2022-502184-38-00 Phase II Rapidly progressive glomerulonephritis Alentis Therapeutics AG
A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting

2024-517335-46-00 Phase II Bladder cancer Merck Sharp & Dohme LLC
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517457-27-00 Phase III Chronic Obstructive Pulmonary Disease (COPD) AstraZeneca AB
A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting

2024-517545-13-00 Phase III/IV Neovascular Age-Related Macular Degeneration F. Hoffmann-La Roche AG
Pilot Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nona… Recruiting

2024-511788-27-01 Phase II non-alcoholic hepatic steatosisalcoholic hepatic steatosis CHRU De Nancy
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Phase III/IV Chron's Disease Takeda Development Center Americas Inc.
Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting

2023-506935-14-01 Phase III Ischemic stroke CHRU De Nancy
Evaluation of the efficacy of sphenopalatine block in headache in patients with non-traumatic subarachnoid hemorrhage (SAH) after training o… Recruiting

2024-514282-19-00 Phase II subarachnoid hemorrhage Centre Hospitalier Universitaire Grenoble Alpes
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting

2024-517432-21-00 Phase II Gynecological Cancers Corcept Therapeutics Inc.
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours Recruiting

2024-519184-18-00 Phase I (FiH) Advanced Solid Tumour Ipsen Pharma
An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan… Recruiting

2024-515280-60-00 Phase III Lupus nephritis Novartis Pharma AG
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun… Recruiting

2023-506539-14-00 Phase I (Other) Oncology Systimmune Inc.
Blocage de l'interféron-ɣ par le ruxolitinib pour le traitement de la myosite à inclusion : un essai de phase IIb Recruiting

2023-507666-32-00 Phase II Inclusion body Myositis Assistance Publique Hopitaux De Paris
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla… Recruiting

2024-514341-10-00 Phase I Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or… Janssen Cilag International
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with IH Recruiting

2024-517712-29-00 Phase II Idiopathic Hypersomnia (IH) Takeda Development Center Americas Inc.
Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort… Recruiting

2024-519116-14-00 Phase II Asthma AstraZeneca AB
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 o… Recruiting

2024-517101-87-00 Phase III Intestinal Malabsorption Elgan Pharma Ltd.
ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca… Recruiting

2023-504511-32-00 Phase III Any patients ≥18 years old, eligible for transfemoral TAVI w… Assistance Publique Hopitaux De Paris
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Phase III Metastatic hormone naïve prostate cancer (mHNPC) European Organisation For Research And Treatment Of Cancer
A clinical study of MK-3120 in people with solid tumors (MK-3120-002) Recruiting

2024-516817-19-00 Phase I/II Advanced/metastatic solid tumor disease Merck Sharp & Dohme LLC
A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting

2024-517147-31-00 Phase I/II Tumours, Gynecological Glaxosmithkline Research & Development Limited

Showing 1,417–1,440 of 4,500 trials

← All countries